Pharmerging markets will be a $500bn 'game changer,' says Reva

By Dan Stanton

- Last updated on GMT

Emerging markets will be a 'game changer' for industry, says Reva

Related tags Bric European union

‘Pharmerging markets’ have extended beyond Brazil, Russia, India and China (BRIC) and will be worth $500bn by 2020, according to Reva Pharma.

“By 2016, the global pharma industry is expected to generate an estimated 30% of its total sales in emerging markets,”​ Gurpreet Sandhu, Managing Director of Indian contract manufacturer Reva Pharma told delegates at last week’s CPhI Pre-Connect Congress in Madrid.

This is a large jump from 2010, when emerging markets represented 18% of total sales but by 2020 “there will be $500bn coming out of the growth markets and this is a total game changer,”​ according to Sandhu.

“Pharmerging markets are a key driver across the whole industry - not just for Big Pharma but for the Big Generics firms as well,”​ he said.

The pharmerging markets have traditionally been viewed as the BRIC countries, and they continue to see low double-digit growth* but Sandhu said firms will be targeting countries including Mexico, Turkey, Poland, Venezuela, Argentina, Indonesia, Vietnam, Romania, Egypt, Ukraine, Pakistan, Thailand and South Africa as the next tier of markets demanding greater volumes of medicines.

In 2012, the top 10 pharma markets were, in order, the US, Japan, China, Germany, France, Brazil, Italy, Canada, UK and Spain, but by 2017 India and Russia will push out UK and Spain.

“Already healthcare spending in emerging markets has overtaken that of the top five EU countries – Germany, France, Italy, UK and Spain,”​ and this trend will continue, he said.

*Citing IMS Health figures, Sandhu said the 2013-7 Compound Annual Growth Rates (CAGR) were: Brazil 11-14%, Russia 9-12%, India 11-14%, and China 15-18%.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more